HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor, diabetes education nurse, or pharmacist. NovoRapid ® contains the active ingredient ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a biosimilar insulin aspart (100 units/mL) manufactured by Sanofi. The ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor, diabetes education nurse, or pharmacist. NovoRapid ® contains the active ingredient ...
The US Food and Drug Administration (FDA) has approved the use of the faster-acting insulin aspart (Fiasp 100 units/mL, Novo Nordisk) for pediatric patients with diabetes. Faster aspart can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback